Cancer BiologybioRxivPreprint
Development of a liposomal formulation of a TKI: the active loading of erlotinib.HCl
Cindy Schelker, Victoria Trap, Gerrit Borchard, Patrycja M. Nowak-Sliwinska
This study develops a liposomal formulation of erlotinib.HCl, demonstrating successful active loading and highlighting differences in toxicity and uptake between 2D cell lines and patient-derived organoids.
DOI 10.1101/2025.06.06.658400